Stella Bijkerk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stella Bijkerk has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Frank L. J. Visseren
University Medical Center Utrecht
5 shared publications - Jannick A. N. Dorresteijn
University Medical Center Utrecht
5 shared publications - Steven H. J. Hageman
University Medical Center Utrecht
5 shared publications - Emanuele Di Angelantonio
Human Technopole, Milan, Italy
4 shared publications Alejandro Pomi
Sociedad Uruguaya de Cardiología, Cardiólogo del Hospital Español , Montevideo
3 shared publications- Alfredo Cabrera-Villamizar
Hospital Universitario Fundación Santa Fé de Bogotá
3 shared publications
Latest Publications
- 29 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Development and external validation of the SCORE2 models in Latin America and the Caribbean (SCORE2-LAC) to estimate 10-year cardiovascular disease risk
Background and Aims: Despite the high burden of cardiovascular disease (CVD) in Latin America and the Caribbean (LAC), risk prediction models adapted for use in LAC populations remain limited. The aim of this study was to recalibrate the Systematic COronary Risk Evaluation 2 (SCORE2) risk models for estimating 10-year CVD risk in individuals without prior CVD or diabetes mellitus in LAC, resulting in the SCORE2 Latin America and the Caribbean (SCORE2-LAC) models. Methods: Sex-specific, competing risk-adjusted SCORE2 models were recalibrated to contemporary CVD incidence across four risk regions, defined by country-level age- and sex-standardized CVD mortality rates, using region-specific risk factor distributions. Cardiovascular disease incidence was estimated from CVD mortality data and ratios of the total first-to-fatal CVD events, derived from 40 237 152 individuals (1 261 329 CVD events). External validation included 132 512 individuals without prior CVD or diabetes from 11 cohorts across seven countries (3938 CVD events). Discrimination was assessed using Harrell’s C-index. Results: In the external validation datasets, the pooled C-index of SCORE2-LAC was .740 [95% confidence interval (CI) .716–.763], with cohort-specific C-indices ranging from .674 (95% CI .588–.761) to .789 (95% CI .747–.831). Estimated CVD risk varied several-fold across the four LAC risk regions. For a 50-year-old non-smoker with a systolic blood pressure of 140 mmHg, total cholesterol of 213 mg/dL (5.5 mmol/L), and HDL cholesterol of 50 mg/dL (1.3 mmol/L), the predicted risk ranged from 3% in low-risk countries to 10% in very-high-risk countries for women, and from 4% to 10% for men. Conclusions: The SCORE2-LAC models provide region-specific contemporary estimates of 10-year CVD risk in apparently healthy individuals, enabling identification of individuals at high CVD risk across LAC.
- 29 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Development and external validation of the SCORE2 models in Latin America and the Caribbean (SCORE2-LAC) to estimate 10-year cardiovascular disease risk
Background and Aims: Despite the high burden of cardiovascular disease (CVD) in Latin America and the Caribbean (LAC), risk prediction models adapted for use in LAC populations remain limited. The aim of this study was to recalibrate the Systematic COronary Risk Evaluation 2 (SCORE2) risk models for estimating 10-year CVD risk in individuals without prior CVD or diabetes mellitus in LAC, resulting in the SCORE2 Latin America and the Caribbean (SCORE2-LAC) models. Methods: Sex-specific, competing risk-adjusted SCORE2 models were recalibrated to contemporary CVD incidence across four risk regions, defined by country-level age- and sex-standardized CVD mortality rates, using region-specific risk factor distributions. Cardiovascular disease incidence was estimated from CVD mortality data and ratios of the total first-to-fatal CVD events, derived from 40 237 152 individuals (1 261 329 CVD events). External validation included 132 512 individuals without prior CVD or diabetes from 11 cohorts across seven countries (3938 CVD events). Discrimination was assessed using Harrell’s C-index. Results: In the external validation datasets, the pooled C-index of SCORE2-LAC was .740 [95% confidence interval (CI) .716–.763], with cohort-specific C-indices ranging from .674 (95% CI .588–.761) to .789 (95% CI .747–.831). Estimated CVD risk varied several-fold across the four LAC risk regions. For a 50-year-old non-smoker with a systolic blood pressure of 140 mmHg, total cholesterol of 213 mg/dL (5.5 mmol/L), and HDL cholesterol of 50 mg/dL (1.3 mmol/L), the predicted risk ranged from 3% in low-risk countries to 10% in very-high-risk countries for women, and from 4% to 10% for men. Conclusions: The SCORE2-LAC models provide region-specific contemporary estimates of 10-year CVD risk in apparently healthy individuals, enabling identification of individuals at high CVD risk across LAC.
- Open Access
- 1 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (7) , 1212-1222
Comparison of different long-term cardiovascular disease risk prediction horizons to guide preventive drug treatment in apparently healthy individuals
Aims: Guideline-recommended long-term cardiovascular disease (CVD) risk prediction models use varying time horizons. This study compared which risk horizon (risk until ages 80 or 95 years, or 30-year risk) most effectively guides preventive treatment in apparently healthy individuals. Methods and results: CVD risks for all horizon were estimated using the LIFE-CVD2 model in individuals aged 35–69 years without CVD or diabetes from the Dutch ELAN registry (2007–2024; n = 364 003) and the EPIC-InterAct subcohort (1992–1998; n = 8813). Individuals in the top risk decile were compared across time horizons. Simulating blood pressure- and lipid-lowering therapy, the impact of using either time horizon was assessed by the expected gain in CVD-free life years and lifetime CVD events prevented. Individuals identified by 30-year risk were predominantly older and largely overlapped with 10-year risk (46%). In contrast, risk until ages 80 and 95 years showed less overlap with 10-year risk (18% and 20%, respectively) and identified more young men in the highest risk decile. Treatment guided by risk until ages 80 and 95 years yielded a median gain of 2.6 [IQR 2.2–2.9] CVD-free life years per person treated, with prevention of 4434 and 4658 CVD events, respectively, compared with 1.8 [IQR 1.4–1.9] years and 4215 events for 30-year risk. A hybrid strategy combining 10-year risk with risk until age 80 years yielded a median gain of 2.5 [IQR 2.1–3.0] CVD-free life years. Conclusion: Long-term CVD risk estimation until age 80 years offers a pragmatic approach to identify younger high-risk individuals not captured by 10-year risk who may benefit from preventive treatment.
- 1 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (7) , 1212-1222
Open AccessComparison of different long-term cardiovascular disease risk prediction horizons to guide preventive drug treatment in apparently healthy individuals
Aims: Guideline-recommended long-term cardiovascular disease (CVD) risk prediction models use varying time horizons. This study compared which risk horizon (risk until ages 80 or 95 years, or 30-year risk) most effectively guides preventive treatment in apparently healthy individuals. Methods and results: CVD risks for all horizon were estimated using the LIFE-CVD2 model in individuals aged 35–69 years without CVD or diabetes from the Dutch ELAN registry (2007–2024; n = 364 003) and the EPIC-InterAct subcohort (1992–1998; n = 8813). Individuals in the top risk decile were compared across time horizons. Simulating blood pressure- and lipid-lowering therapy, the impact of using either time horizon was assessed by the expected gain in CVD-free life years and lifetime CVD events prevented. Individuals identified by 30-year risk were predominantly older and largely overlapped with 10-year risk (46%). In contrast, risk until ages 80 and 95 years showed less overlap with 10-year risk (18% and 20%, respectively) and identified more young men in the highest risk decile. Treatment guided by risk until ages 80 and 95 years yielded a median gain of 2.6 [IQR 2.2–2.9] CVD-free life years per person treated, with prevention of 4434 and 4658 CVD events, respectively, compared with 1.8 [IQR 1.4–1.9] years and 4215 events for 30-year risk. A hybrid strategy combining 10-year risk with risk until age 80 years yielded a median gain of 2.5 [IQR 2.1–3.0] CVD-free life years. Conclusion: Long-term CVD risk estimation until age 80 years offers a pragmatic approach to identify younger high-risk individuals not captured by 10-year risk who may benefit from preventive treatment.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Development and External Validation of the SCORE2 Models in Latin America and the Caribbean (SCORE2-LAC) to Estimate 10-Year Cardiovascular Disease Risk
Background and Aims Despite the high burden of cardiovascular disease (CVD) in Latin America and the Caribbean (LAC), risk prediction models adapted for use in LAC populations remain limited. The aim of this study was to recalibrate the Systematic COronary Risk Evaluation 2 (SCORE2) risk models for estimating 10-year CVD risk in individuals without prior CVD or diabetes mellitus in LAC, resulting in the SCORE2 Latin America and the Caribbean (SCORE2-LAC) models. Methods Sex-specific, competing risk-adjusted SCORE2 models were recalibrated to contemporary CVD incidence across four risk regions, defined by country-level age- and sex-standardized CVD mortality rates, using region-specific risk factor distributions. Cardiovascular disease incidence was estimated from CVD mortality data and ratios of the total first-to-fatal CVD events, derived from 40 237 152 individuals (1 261 329 CVD events). External validation included 132 512 individuals without prior CVD or diabetes from 11 cohorts across seven countries (3938 CVD events). Discrimination was assessed using Harrell’s C-index. Results In the external validation datasets, the pooled C-index of SCORE2-LAC was .740 [95% confidence interval (CI) .716–.763], with cohort-specific C-indices ranging from .674 (95% CI .588–.761) to .789 (95% CI .747–.831). Estimated CVD risk varied several-fold across the four LAC risk regions. For a 50-year-old non-smoker with a systolic blood pressure of 140 mmHg, total cholesterol of 213 mg/dL (5.5 mmol/L), and HDL cholesterol of 50 mg/dL (1.3 mmol/L), the predicted risk ranged from 3% in low-risk countries to 10% in very-high-risk countries for women, and from 4% to 10% for men. Conclusions The SCORE2-LAC models provide region-specific contemporary estimates of 10-year CVD risk in apparently healthy individuals, enabling identification of individuals at high CVD risk across LAC. Structured Graphical
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Open AccessDevelopment and External Validation of the SCORE2 Models in Latin America and the Caribbean (SCORE2-LAC) to Estimate 10-Year Cardiovascular Disease Risk
Background and Aims Despite the high burden of cardiovascular disease (CVD) in Latin America and the Caribbean (LAC), risk prediction models adapted for use in LAC populations remain limited. The aim of this study was to recalibrate the Systematic COronary Risk Evaluation 2 (SCORE2) risk models for estimating 10-year CVD risk in individuals without prior CVD or diabetes mellitus in LAC, resulting in the SCORE2 Latin America and the Caribbean (SCORE2-LAC) models. Methods Sex-specific, competing risk-adjusted SCORE2 models were recalibrated to contemporary CVD incidence across four risk regions, defined by country-level age- and sex-standardized CVD mortality rates, using region-specific risk factor distributions. Cardiovascular disease incidence was estimated from CVD mortality data and ratios of the total first-to-fatal CVD events, derived from 40 237 152 individuals (1 261 329 CVD events). External validation included 132 512 individuals without prior CVD or diabetes from 11 cohorts across seven countries (3938 CVD events). Discrimination was assessed using Harrell’s C-index. Results In the external validation datasets, the pooled C-index of SCORE2-LAC was .740 [95% confidence interval (CI) .716–.763], with cohort-specific C-indices ranging from .674 (95% CI .588–.761) to .789 (95% CI .747–.831). Estimated CVD risk varied several-fold across the four LAC risk regions. For a 50-year-old non-smoker with a systolic blood pressure of 140 mmHg, total cholesterol of 213 mg/dL (5.5 mmol/L), and HDL cholesterol of 50 mg/dL (1.3 mmol/L), the predicted risk ranged from 3% in low-risk countries to 10% in very-high-risk countries for women, and from 4% to 10% for men. Conclusions The SCORE2-LAC models provide region-specific contemporary estimates of 10-year CVD risk in apparently healthy individuals, enabling identification of individuals at high CVD risk across LAC. Structured Graphical
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Desenvolvimento e Validação Externa dos Modelos SCORE2 na América Latina e no Caribe (SCORE2-LAC) para Estimar o Risco de Doenças Cardiovasculares em 10 Anos
Resumo Fundamento e objetivos Apesar da elevada carga de doença cardiovascular (DCV) na América Latina e no Caribe (ALC), ainda são escassos os modelos de predição de risco adaptados para uso nas populações da ALC. O objetivo deste estudo foi recalibrar os modelos de risco Systematic COronary Risk Evaluation 2 (SCORE2) para estimar o risco de DCV em 10 anos em indivíduos sem DCV prévia ou diabetes melito na ALC, dando origem aos modelos SCORE2 para a América Latina e o Caribe (SCORE2-LAC). Métodos Os modelos SCORE2 específicos por sexo e ajustados para riscos competitivos foram recalibrados de acordo com a incidência atual de DCV em quatro regiões de risco, definidas com base nas taxas nacionais de mortalidade por DCV padronizadas por idade e sexo. Para a recalibração, foram utilizadas distribuições de fatores de risco específicas de cada região. A incidência de DCV foi estimada com base nos dados de mortalidade por DCV e nas razões entre o total de primeiros eventos e os eventos fatais de DCV, obtidas de 40 237 152 indivíduos (1 261 329 eventos de DCV). A validação externa incluiu 132 512 indivíduos sem DCV prévia ou diabetes provenientes de 11 coortes de sete países (3938 eventos de DCV). A discriminação foi avaliada por meio do índice C de Harrell. Resultados Nos conjuntos de dados de validação externa, o índice C combinado do SCORE2-LAC foi de 0,740 (intervalo de confiança de 95% [IC 95%]: 0,716-0,763), com índices C específicos de cada coorte variando de 0,674 (IC 95%: 0,588-0,761) a 0,789 (IC 95%: 0,747-0,831). O risco estimado de DCV variou substancialmente entre as quatro regiões de risco da ALC. Para uma pessoa de 50 anos, não fumante, com pressão arterial sistólica de 140 mmHg, colesterol total de 213 mg/dL (5,5 mmol/L) e colesterol da lipoproteína de alta densidade de 50 mg/dL (1,3 mmol/L), o risco previsto variou de 3% nos países de baixo risco a 10% nos países de risco muito alto entre as mulheres e de 4% a 10% entre os homens. Conclusões Os modelos SCORE2-LAC fornecem estimativas atuais e específicas por região do risco de DCV em 10 anos em indivíduos aparentemente saudáveis, permitindo identificar aqueles com alto risco de DCV em toda a ALC. Resumo Gráfico Estruturado.
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Open AccessDesenvolvimento e Validação Externa dos Modelos SCORE2 na América Latina e no Caribe (SCORE2-LAC) para Estimar o Risco de Doenças Cardiovasculares em 10 Anos
Resumo Fundamento e objetivos Apesar da elevada carga de doença cardiovascular (DCV) na América Latina e no Caribe (ALC), ainda são escassos os modelos de predição de risco adaptados para uso nas populações da ALC. O objetivo deste estudo foi recalibrar os modelos de risco Systematic COronary Risk Evaluation 2 (SCORE2) para estimar o risco de DCV em 10 anos em indivíduos sem DCV prévia ou diabetes melito na ALC, dando origem aos modelos SCORE2 para a América Latina e o Caribe (SCORE2-LAC). Métodos Os modelos SCORE2 específicos por sexo e ajustados para riscos competitivos foram recalibrados de acordo com a incidência atual de DCV em quatro regiões de risco, definidas com base nas taxas nacionais de mortalidade por DCV padronizadas por idade e sexo. Para a recalibração, foram utilizadas distribuições de fatores de risco específicas de cada região. A incidência de DCV foi estimada com base nos dados de mortalidade por DCV e nas razões entre o total de primeiros eventos e os eventos fatais de DCV, obtidas de 40 237 152 indivíduos (1 261 329 eventos de DCV). A validação externa incluiu 132 512 indivíduos sem DCV prévia ou diabetes provenientes de 11 coortes de sete países (3938 eventos de DCV). A discriminação foi avaliada por meio do índice C de Harrell. Resultados Nos conjuntos de dados de validação externa, o índice C combinado do SCORE2-LAC foi de 0,740 (intervalo de confiança de 95% [IC 95%]: 0,716-0,763), com índices C específicos de cada coorte variando de 0,674 (IC 95%: 0,588-0,761) a 0,789 (IC 95%: 0,747-0,831). O risco estimado de DCV variou substancialmente entre as quatro regiões de risco da ALC. Para uma pessoa de 50 anos, não fumante, com pressão arterial sistólica de 140 mmHg, colesterol total de 213 mg/dL (5,5 mmol/L) e colesterol da lipoproteína de alta densidade de 50 mg/dL (1,3 mmol/L), o risco previsto variou de 3% nos países de baixo risco a 10% nos países de risco muito alto entre as mulheres e de 4% a 10% entre os homens. Conclusões Os modelos SCORE2-LAC fornecem estimativas atuais e específicas por região do risco de DCV em 10 anos em indivíduos aparentemente saudáveis, permitindo identificar aqueles com alto risco de DCV em toda a ALC. Resumo Gráfico Estruturado.
- 14 February 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (16) , 2936-2945
Socioeconomic disparities and risk of recurrent cardiovascular events and cardiovascular disease-free life expectancy in patients with established cardiovascular disease
Aims: This study aimed to evaluate whether lower socioeconomic status (SES) is related to a higher risk of recurrent cardiovascular disease (CVD) events and reduced CVD-free life expectancy in a large cohort of patients with established CVD. Methods and results: A total of 9477 patients with established CVD from the Utrecht Cardiovascular Cohort—Secondary Manifestations of ARTerial disease (1996–2022) study were included. SES scores were determined at the neighbourhood level using scores provided by the Netherlands Institute for Social Research, based on income, education, and unemployment. The relationship between SES and recurrent CVD events was analysed using Cox proportional hazard models, adjusted for age, sex, and traditional CVD risk factors. Event-free life expectancy across SES quintiles was assessed using Kaplan–Meier survival estimates, with age as the timescale and accounting for competing risks. Over a median follow-up of 9.0 years [inter-quartile interval (IQI): 4.8–14.1], 2090 recurrent CVD events occurred. Unfavourable CVD risk factors were more prevalent among low SES patients, who less frequently used preventive drug treatment. After adjusting for age and sex, patients in the lowest SES quintile had a higher risk of recurrent events compared with the highest SES quintile [hazard ratio (HR): 1.35; 95% confidence interval (CI): 1.17–1.56]. This relationship persisted after adjusting for CVD risk factors potentially mediating the effect. The median event-free life expectancy was 5.5 years (95% CI: 2.8–8.0) shorter comparing the lowest with highest SES quintile. Conclusion: Among patients with established CVD, lower SES is related to a higher risk of recurrent CVD events independent of CVD risk factors and to a shorter CVD-free survival. These findings underscore the need for targeted interventions to reduce health disparities.
- 14 February 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (16) , 2936-2945
Socioeconomic disparities and risk of recurrent cardiovascular events and cardiovascular disease-free life expectancy in patients with established cardiovascular disease
Aims: This study aimed to evaluate whether lower socioeconomic status (SES) is related to a higher risk of recurrent cardiovascular disease (CVD) events and reduced CVD-free life expectancy in a large cohort of patients with established CVD. Methods and results: A total of 9477 patients with established CVD from the Utrecht Cardiovascular Cohort—Secondary Manifestations of ARTerial disease (1996–2022) study were included. SES scores were determined at the neighbourhood level using scores provided by the Netherlands Institute for Social Research, based on income, education, and unemployment. The relationship between SES and recurrent CVD events was analysed using Cox proportional hazard models, adjusted for age, sex, and traditional CVD risk factors. Event-free life expectancy across SES quintiles was assessed using Kaplan–Meier survival estimates, with age as the timescale and accounting for competing risks. Over a median follow-up of 9.0 years [inter-quartile interval (IQI): 4.8–14.1], 2090 recurrent CVD events occurred. Unfavourable CVD risk factors were more prevalent among low SES patients, who less frequently used preventive drug treatment. After adjusting for age and sex, patients in the lowest SES quintile had a higher risk of recurrent events compared with the highest SES quintile [hazard ratio (HR): 1.35; 95% confidence interval (CI): 1.17–1.56]. This relationship persisted after adjusting for CVD risk factors potentially mediating the effect. The median event-free life expectancy was 5.5 years (95% CI: 2.8–8.0) shorter comparing the lowest with highest SES quintile. Conclusion: Among patients with established CVD, lower SES is related to a higher risk of recurrent CVD events independent of CVD risk factors and to a shorter CVD-free survival. These findings underscore the need for targeted interventions to reduce health disparities.